Efficacy and safety of clonazepam in refractory neurally mediated syncope

PACE - Pacing and Clinical Electrophysiology

Volumn 22, Issue 2, 1999, Pages 307-314

  Kadri, Nazih N ^a   Hee, Tom T ^a   Rovang, Karen S ^a   Mohiuddin, Syed M ^a   Ryan, Timothy ^a   Ashraf, Raashid ^a   Huebert, Vincent ^a   Hilleman, Daniel E ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Clonazepam; Neurally mediated syncope

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DISOPYRAMIDE; EPHEDRINE; FLUDROCORTISONE; FLUOXETINE; ISOPRENALINE; MINERALOCORTICOID; PINDOLOL; PROPANTHELINE BROMIDE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIET THERAPY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; MALE; NEUROLOGIC DISEASE; RECURRENT DISEASE; SYNCOPE; TILT TABLE TEST; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033044192     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1999.tb00443.x     Document Type: Article

References (40)

1. 1. Abboud FM. Neurocardiogenic syncope. N Engl J Med 1993; 328:1117-1120.
2. 2. Sra JS, Jazayeri MR, Dhala A, et al. Neurocardiogenic syncope. Diagnosis, mechanisms, and treatment. Cardiol Clin 1993; 11:183-191.
3. 3. Grubb BP, Kosinski D. Current trends in etiology, diagnosis, and management of neurocardiogenic syncope. Curr Opin Cardiol 1996; 11:32-41.
4. 4. Goldenberg IF, Almquist A, Dunbar DN, et al. Prevention of neurally-mediated syncope by selective beta-1 adrenoceptor blockade. (abstract) Circulation 1987; 76(Suppl. IV):IV-133.
5. 5. Sra JS, Murthy VS, Jazayeri MR, et al. Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol 1992; 19:402-408.
6. 6. Natale A, Sra J, Dhala W, et al. Efficacy of different treatment strategies for neurocardiogenic syncope. PACE 1995; 18(Pt. I):655-662.
7. 7. Lippman N, Stein KM, Lerman BB. Differential therapeutic responses of patients with isoproterenol-dependent and isoproterenol-independent vasodepressor syncope. Am Heart J 1994; 128: 1110-1116.
8. 8. Milstein S, Buetikofer J, Dunnigan A, et al. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol 1990; 65:1339-1344.
9. 9. Sra JS, Jazayeri MR, Avitall B, et al. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole. N Engl J Med 1993; 328:1085-1090.
10. 10. McLaran CJ, Gersh BJ, Osborn MJ, et al. Increased vagal tone as an isolated finding in patients undergoing electrophysiological testing for recurrent syncope: Response to long term anticholinergic agents. Br Heart J 1986; 55:53-57.
11. 11. Wang CC, Yeh SJ, Wen MS, et al. Worsening of vasovagal syncope after beta-blocker therapy. Chest 1994; 106:963-965.
12. 12. Kelly PA, Mann DE, Adler SW, et al. Low dose disopyramide often fails to prevent neurogenic syncope during head-up tilt testing. PACE 1994; 17:573-576.
13. 13. Leor J, Rotstein Z, Vered Z, et al. Absence of tachycardia during tilt test predicts failure of β-blocker therapy in patients with neurocardiogenic syncope. Am Heart J 1994; 127:1539-1543.
14. 14. Huang CY, McLeo JG, Sampson D, et al. Clonazepam in the treatment of epilepsy. Med J Aust 1974; 2:5-8.
15. 15. Sato S. Clonazepam. In R Levy, R Mattson, B Meldrum, et al (eds.): Antiepileptic Drugs. 3rd ed. New York, NY, Raven Press Ltd., 1989, pp. 765-784.
16. 16. Sra JS, Anderson AJ, Sheikh SH, et al. Unexplained syncope evaluated by electrophysiologic studies and head-up tilt testing. Ann Intern Med 1991; 114:1013-1019.
17. 17. Nelson S, Stanley M, Love C, et al. Autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991; 151:2425-2429.
18. 18. Susmano A, Volgman A, Buckinham T. Beneficial effects of dextroamphetamine in the treatment of vasodepressor syncope. PACE 1993; 16:1235-1238.
19. 19. Theodorakis GN, Kremastinos DT, Stefanakis GS, et al. The effectiveness of β-blockade and its influence on heart rate variability in vasovagal patients. Eur Heart J 1993; 14:1499-1507.
20. 20. Williams CC, Bernhardt DT. Syncope in athletes. Sports Med 1995; 19:223-224.
21. 21. Grubb BP, Temesy-Armos PN, Samoil D, et al. Tilt-table testing in the evaluation and management of athletes with recurrent exercise-induced syncope. Med Sci Sports Exerc 1993; 25:24-28.
22. 22. Grubb BP, Temesy-Armos P, Moore J, et al. The use of head-upright tilt testing in the evaluation and management of syncope in children and adolescents. PACE 1992; 15:742-748.
23. 23. Scott WA, Pongiglione G, Bromberg BI, et al. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995; 76:400-402.
24. 24. Grubb BP, Wolfe DA, Samoil D, et al. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. PACE 1993; 16:458-464.
25. 25. Grubb BP, Samoil D, Kosinski D, et al. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 1994; 24:490-494.
26. 26. Grubb BP, Kosinski D. Preliminary observations of the effects of venlafoxine hydrochloride in the treatment of severe refractory orthostatic hypotension. J Serotonin Res 1996; 3:85-89.
27. 27. Glick C, Yu PN. Hemodynamic changes during spontaneous vasovagal reactions. Am J Med 1963; 34:42-45.
28. 28. Thoren P. Role of cardiac C-fibers in cardiovascular control. Rev Physiol Biochem Pharmacol 1979; 86:1-94.
29. 29. Epstein SE, Stampfer M, Beiser GP. Role of capacitance and resistance vessels in vasovagal syncope. Circulation 1968; 37:524-533.
30. 30. Mark AL. The Bezold-Jarish reflex revisited: Clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol 1983; 1: 90-92.
31. 31. Grubb BP, Gerard G, Roush K, et al. Cerebral vasoconstriction during upright tilt induced syncope: A paradoxic and unexpected response. Circulation 1991; 84:1157-1165.
32. 32. Browne RR. Clonazepam: A review of a new anti-convulsant drug. Arch Neruol 1976; 33:326-332.
33. 33. Arnt J, Christensen AV, Scheel-Krueger J. Benzodiazepines potentiate GABA-dopamine-dependent stereotyped gnawing in mice. J Pharm Pharmacol 1979; 31:56-58.
34. 34. Weiner WJ, Goetz C, Nausieda PA, et al. Clonazepam and 5-hydroxytryptophan-induced myoclonic stereotype. Eur J Pharmacol 1977; 46: 21-24.
35. 35. Jenner P, Marsden CD, Prat J, et al. Altered serotoninergic activity in mouse brain induced by clonazepam. Br J Pharmacol 1978; 64:432.
36. 36. Morgan DA, Thoren P, Wilczynski E, et al. Serotonergic mechanism mediate renal sympathoinhibition during severe hemorrhage in rats. Am J Physiol 1988; 255:H496-H502.
37. 37. Kuhn D, Wolfe W, Lovenberg W. Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension 1980; 2:243-245.
38. 38. Abboud F. Neurocardiogenic syncope. N Engl J Med 1993; 328:1117-1119.
39. 39. Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, et al. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol 1995; 25:65-69.
40. 40. Lund M, Trolle E. Clonazepam in the treatment of epilepsy. Acta Neurol Scand 1973; 49:82-90.